These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 29236943)
41. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial. Specenier PM; Remenar E; Buter J; Schrijvers DL; Bergamini C; Licitra LF; Awada A; Clement PM; Fortpied C; Menis J; Vermorken JB Ann Oncol; 2017 Sep; 28(9):2219-2224. PubMed ID: 28911062 [TBL] [Abstract][Full Text] [Related]
42. Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of China. Zang J; Xu M; Li C; Zhao L; Luo S; Wang J; Shi M J Cancer Res Clin Oncol; 2020 Sep; 146(9):2369-2378. PubMed ID: 32363479 [TBL] [Abstract][Full Text] [Related]
43. Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial. Dai J; Zhang B; Su Y; Pan Y; Ye Z; Cai R; Qin G; Kong X; Mo Y; Zhang R; Liu Z; Xie Y; Ruan X; Jiang W JAMA Oncol; 2024 Apr; 10(4):456-463. PubMed ID: 38329737 [TBL] [Abstract][Full Text] [Related]
44. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. Kim R; Hahn S; Shin J; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS Cancer Res Treat; 2016 Jul; 48(3):907-16. PubMed ID: 26582394 [TBL] [Abstract][Full Text] [Related]
45. Effect of nimotuzumab and PF induction chemotherapy combined with concurrent chemoradiotherapy in treating locally advanced nasopharyngeal carcinoma. Gao M; Yuan T; Zhang F J BUON; 2021; 26(1):116-123. PubMed ID: 33721441 [TBL] [Abstract][Full Text] [Related]
46. Low-dose fractionated radiation with induction docetaxel and cisplatin followed by concurrent cisplatin and radiation therapy in locally advanced nasopharyngeal cancer: A randomized phase II-III trial. Al-Rajhi NM; Khalil EM; Ahmad S; Soudy H; AlGhazi M; Fatani DM; Memon M; Abouzied M; Khafaga YM Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):199-205. PubMed ID: 32504593 [TBL] [Abstract][Full Text] [Related]
47. In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation. Jun M; Pinto H; Le QT; Quon A; Hara W; Coty J; McMillan A; Lu R; Winters E; Lira R; Colevas AD PLoS One; 2023; 18(2):e0276651. PubMed ID: 36730145 [TBL] [Abstract][Full Text] [Related]
48. Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma. Kua VF; Ismail F; Chee Ee Phua V; Aslan NM Asian Pac J Cancer Prev; 2013; 14(2):1121-6. PubMed ID: 23621198 [TBL] [Abstract][Full Text] [Related]
49. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials. Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131 [TBL] [Abstract][Full Text] [Related]
50. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653 [TBL] [Abstract][Full Text] [Related]
51. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial. Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J; Sun Y Int J Cancer; 2019 Jul; 145(1):295-305. PubMed ID: 30613964 [TBL] [Abstract][Full Text] [Related]
52. Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck. Katori H; Tsukuda M Clin Oncol (R Coll Radiol); 2005 May; 17(3):148-52. PubMed ID: 15900997 [TBL] [Abstract][Full Text] [Related]
53. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. Ou D; Blanchard P; El Khoury C; De Felice F; Even C; Levy A; Nguyen F; Janot F; Gorphe P; Deutsch E; Temam S; Tao Y Oral Oncol; 2016 Nov; 62():114-121. PubMed ID: 27865364 [TBL] [Abstract][Full Text] [Related]
54. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. Chen Y; Sun Y; Liang SB; Zong JF; Li WF; Chen M; Chen L; Mao YP; Tang LL; Guo Y; Lin AH; Liu MZ; Ma J Cancer; 2013 Jun; 119(12):2230-8. PubMed ID: 23576020 [TBL] [Abstract][Full Text] [Related]
55. Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial. Driessen CML; Groenewoud JMM; de Boer JP; Gelderblom H; van der Graaf WTA; Prins JB; Kaanders JHAM; van Herpen CML Support Care Cancer; 2018 Apr; 26(4):1233-1242. PubMed ID: 29230548 [TBL] [Abstract][Full Text] [Related]
56. [Analysis of follow-up results of chrono-chemotherapy or conventional chemotherapy combined with intensity modulated radiotherapy in locally advanced nasopharyngeal carcinoma]. Liu KQ; Jin F; Jiang H; Wu WL; Li YY; Long JH; Luo XL; Gong XY; Chen XX; Liu LN; Gan JY; Zhou JJ Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):133-138. PubMed ID: 32135648 [No Abstract] [Full Text] [Related]
57. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response. Liu SL; Sun XS; Yan JJ; Chen QY; Lin HX; Wen YF; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Li XY; Lin C; Du YY; Yang ZC; Xiao BB; Yang JH; Tang LQ; Guo L; Mai HQ Radiother Oncol; 2019 Aug; 137():83-94. PubMed ID: 31078941 [TBL] [Abstract][Full Text] [Related]
58. Induction Chemotherapy Followed by Radiotherapy versus Concurrent Chemoradiotherapy in elderly patients with nasopharyngeal carcinoma: finding from a propensity-matched analysis. Zeng Q; Wang J; Lv X; Li J; Yin LJ; Xiang YQ; Guo X BMC Cancer; 2016 Aug; 16(1):693. PubMed ID: 27577729 [TBL] [Abstract][Full Text] [Related]
59. Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial. Janoray G; Pointreau Y; Alfonsi M; Sire C; Geoffrois L; de Raucourt D; Bardet E; Calais MH; Garaud P; Calais G Eur J Cancer; 2020 Jul; 133():86-93. PubMed ID: 32454417 [TBL] [Abstract][Full Text] [Related]
60. Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. Dietz A; Wichmann G; Kuhnt T; Pfreundner L; Hagen R; Scheich M; Kölbl O; Hautmann MG; Strutz J; Schreiber F; Bockmühl U; Schilling V; Feyer P; de Wit M; Maschmeyer G; Jungehülsing M; Schroeder U; Wollenberg B; Sittel C; Münter M; Lenarz T; Klussmann JP; Guntinas-Lichius O; Rudack C; Eich HT; Foerg T; Preyer S; Westhofen M; Welkoborsky HJ; Esser D; Thurnher D; Remmert S; Sudhoff H; Görner M; Bünzel J; Budach V; Held S; Knödler M; Lordick F; Wiegand S; Vogel K; Boehm A; Flentje M; Keilholz U Ann Oncol; 2018 Oct; 29(10):2105-2114. PubMed ID: 30412221 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]